Insertions and deletions in HIV-1 reverse transcriptase: Consequences for drug resistance and viral fitness

Current Pharmaceutical Design

Volumn 12, Issue 15, 2006, Pages 1811-1825

  Menéndez Arias, Luis ^a   Matamoros, Tania ^a   Cases González, Clara E ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Antiretroviral therapy; Drug Resistance; Excision repair; HIV; Nucleoside analogues; Reverse transcriptase; Zidovudine

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BINDING SITE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME STRUCTURE; GENE DELETION; GENE INSERTION; GENE MUTATION; GENETIC CODE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS RESISTANCE;

AMINO ACID SEQUENCE; BASE SEQUENCE; DRUG RESISTANCE, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ALIGNMENT; SEQUENCE DELETION;

EID: 33646528913     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776873608     Document Type: Review

References (154)

1. UNAIDS. AIDS Epidemic Update 2005. Geneve, Switzerland.
2. Menéndez-Arias L. Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol Sci 2002; 23: 381-8.
3. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350: 1023-35.
4. De Clercq E. Antivirals and antiviral strategies. Nat Rev Microbiol 2004; 2: 704-20.
5. Imamichi, T. Action of anti-HIV drugs and resistance: Reverse transcriptase inhibitors and protease inhibitors. Curr Pharm Design 2004; 10: 4039-53.
6. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-9.
7. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337: 725-33.
8. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality in patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
9. Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, et al. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985; 82: 7096-100.
10. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine isolated during prolonged therapy. Science 1989; 243: 1731-4.
11. Mitsuya H, Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/ lymphoadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc Natl Acad Sci USA 1986; 83: 1911-5.
12. Baba M, Pauwels R, Herdewijn P, de Clercq E, Desmyter J, Vandeputte M. Both 2′,3′-dideoxythymidine and its 2′,3′-unsaturated derivative (2′,3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem Biophys Res Commun 1987; 142: 128-34.
13. Shirasaka T, Kavlick MF, Ueno T, Gao W-Y, Kojima E, Alcaide ML, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995; 92: 2398-402.
14. Menéndez-Arias L. Molecular basis of fidelity of DNA synthesis and nucleotide specificity of retroviral reverse transcriptases. Prog Nucl Acid Res Mol Biol 2002; 71: 91-147.
15. Svaroskaia ES, Cheslock SR, Zhang W-H, Hu W-S, Pathak VK. Retroviral mutation rates and reverse transcriptase fidelity. Front Biosci 2003; 8: D117-34.
16. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256: 1783-90.
17. Huang H, Chopra R, Verdine GL, Harrison SC. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 1998; 282: 1669-75.
18. Jacobo-Molina A, Ding J, Nanni RG, Clark AD Jr, Lu X, Tantillo C, et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc Natl Acad Sci USA 1993; 90: 6320-4.
19. Ding J, Das K, Hsiou Y, Sarafianos SG, Clark AD Jr, Jacobo-Molina A, et al. Structural and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 Å resolution. J Mol Biol 1998; 284: 1095-111.
20. Jäger J, Smerdon SJ, Wang J, Boisvert DC, Steitz TA. Comparison of three different crystal forms shows HIV-1 reverse transcriptase displays an internal swivel motion. Structure 1994; 2: 869-76.
21. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004; 30: 115-33.
22. Sharma PL, Nurpeisov V, Hernández-Santiago B, Beltran T, Schinazi RF. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Curr Top Med Chem 2004; 4: 895-919.
23. Otto MJ. New nucleoside reverse transcriptase inhibitors for the treatment of HIV infections. Curr Opin Pharmacol 2004; 4: 431-6.
24. Pauwels R. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. Curr Opin Pharmacol 2004; 4: 437-46.
25. Sarafianos SG, Das K, Hughes SH, Arnold E. Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases. Curr Opin Struct Biol 2004; 14: 716-30.
26. Das K, Lewi PJ, Hughes SH, Arnold E. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog Biophys Mol Biol 2005; 88: 209-31.
27. Rittinger K, Divita G, Goody RS. Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. Proc Natl Acad Sci USA 1995; 92: 8046-9.
28. Spence RA, Kati WM, Anderson KS, Johnson KA. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995; 267: 988-93.
29. Sluis-Cremer N, Temiz NA, Bahar I. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr HIV Res 2004; 2: 323-32.
30. Feng JY, Anderson KS. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase. Biochemistry 1999; 38: 9440-8.
31. Sarafianos SG, Das K, Clark Jr AD, Ding J, Boyer PL, Hughes SH, et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with β-branched amino acids. Proc Natl Acad Sci USA 1999; 96: 10027-32.
32. Deval J, White KL, Miller MD, Parkin NT, Courcambeck J, Halfon P, et al. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem 2004; 279: 509-16.
33. Johnson VA, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: 2005. Top HIV Med 2005; 13: 125-31.
34. Larder BA. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J Gen Virol 1994; 75: 951-7.
35. Pellegrin I, Izopet J, Reynes J, Denayrolles M, Montes P, Pellegrin J-L, et al. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naïve patients receiving stavudine plus didanosine combination therapy. AIDS 1999: 13: 1705-9.
36. Izopet J, Bicart-See A, Pasquier C, Sandres K, Bonnet E, Marchou B, et al. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine. J Med Virol 1999; 59: 507-11
37. Coakley EP, Gillis JM, Hammer SM. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 2000; 14: F9-15.
38. Whitcomb JM, Parkin NT, Chappey C, Hellmann NS, Petropoulos CJ. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 2003; 188: 992-1000.
39. Ross L, Parkin N, Chappey C, Fisher R, St Clair M, Bates M, et al. Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance. AIDS 2004; 18: 1691-6.
40. Rhee SY, Liu T, Ravela J, Gonzales MJ, Shafer RW. Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing. Antimicrob Agents Chemother 2004; 48: 3122-6.
41. Ueno T, Shirasaka T, Mitsuya H. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2′,3′-dideoxynucleoside 5′ triphosphates. J Biol Chem 1995; 270: 23605-11.
42. Shafer RW, Iversen AKN, Winters MA, Aguiniga E, Katzenstein DA, Merigan TC. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J Infect Dis 1995; 172: 70-8.
43. Iversen AKN, Shafer RW, Wehrly K, Winters MA, Mullins JI, Chesebro B, et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 1996; 70: 1086-90.
44. Deval J, Selmi B, Boretto J, Egloff MP, Guerreiro C, Sarfati S, et al. The molecular mechanism of multidrug resistance by the Q151M human immunodeficiency virus type 1 reverse transcriptase and its suppression using α-boranophosphate nucleotide analogues. J Biol Chem 2002; 277: 42097-104.
45. Ray AS, Basavapathruni A, Anderson KS. Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir. J Biol Chem 2002; 277: 40479-90.
46. Jeffrey JL, Feng JY, Qi CCR, Anderson KS, Furman PA. Dioxolane guanosine 5′-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. J Biol Chem 2003; 278: 18971-9.
47. De Antoni A., Foli A., Lisziewcz J, Lori F. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. J Infect Dis 1997; 176: 899-903.
48. Winters MA, Coolley KL, Girard YA, Levee DJ, Hamdan H, Shafer RW, et al. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 1998; 102: 1769-75.
49. Tamalet C, Izopet J, Koch N, Fantini J, Yahi N. Stable rearrangements of the β3-β4 hairpin loop of HIV-1 reverse transcriptase in plasma viruses from patients receiving combination therapy. AIDS 1998; 12: F161-6.
50. De Jong JJ, Goudsmit J, Lukashov VV, Hillebrand ME, Baan E, Huismans R, et al. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS 1999; 13: 75-80.
51. Rakik A, Ait-Khaled M, Griffin P, Thomas DA, Tisdale M, Kleim J-P. for the Abacavir CNA2007 International Study Group. A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. AIDS Res Human Retrovir 1999; 22: 139-45.
52. Lukashov VV, de Ronde A, de Jong JJ, Goudsmit J. Epidemiology of HIV-1 and emerging problems. Int J Antimicrob Agents 2000; 16: 463-6
53. Masquelier B, Race E, Tamalet C, Descamps D, Izopet J, Buffet-Janvresse C, et al. the ANRS AC11 Resistance Study Group. Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): Multicenter study of patients treated with RT inhibitors. Antimicrob Agents Chemother 2001; 45: 1836-42.
54. Tamalet C, Yahi N, Tourrès C, Colson P, Quinson A-M, Poizot-Martin I, et al. Multidrug resistance genotypes (insertions in the β3-β4 finger subdomain and MDR mutations) of HIV-1 reverse transcriptase from extensively treated patients: Incidence and association with other resistance mutations. Virology 2000; 270: 310-6.
55. Mas A, Parera M, Briones C, Soriano V, Martínez MA, Domingo E, et al. Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. EMBO J 2000; 19: 5752-61.
56. Bonfanti P, Faggion I, La Seta Catamancio S, Violin M, Balotta C, Rusconi S. Response to antiretroviral therapy in a patient with an uncommon codon 69 insertion in the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2000; 44: 1767-8.
57. Sato H, Tomita Y, Ebisawa K, Hachiya A, Shibamura K, Shiino T, et al. Augmentation of human immunodeficiency virus type 1 subtype E (CRF01Æ) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase. J Virol 2001; 75: 5604-13
58. Van der Hoek L, Back N, Jebbink MF, de Ronde A, Bakker M, Jurriaans S, et al. Increase multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-acid insert in the reverse transcriptase. J Virol 2005; 79: 3536-43.
59. Van Vaerenbergh K, van Laethem K, Albert J, Boucher CAB, Clotet B, Floridia M, et al. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother 2000; 44: 2109-17.
60. Sugiura W, Matsuda M, Matsuda Z, Abumi H, Okano A, Oishi T, et al. Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors. J Human Virol 1999; 2: 146-53.
61. Yahi N, Tamalet C, Tourrès C, Tivoli N, Ariasi F, Volot F, et al. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: Survey of 787 sequences. J Clin Microbiol 1999; 37: 4099-106
62. Briones C, Mas A, Pérez-Olmeda, M, Altisent C, Domingo E, Soriano V. Prevalence and genetic heterogeneity of the reverse transcriptase T69S-S-X insertion in pretreated HIV-infected patients. Intervirology 2001; 44: 339-43
63. Balotta C, Violin M, Monno L, Bagnarelli P, Riva C, Facchi G, et al. Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1-infected Italian patients with virological failure. J Acquir Immune Defic Syndr 2000; 24: 232-40.
64. Schneider V, Legoff J, Bélec L, Delphin N, Dutreuil C, Kara-Mostefa A, et al. Peptide insertions in reverse transcriptase pol gene of human immunodeficiency virus type 1 as a rare cause of persistent antiretroviral therapeutic failure. Clin Microbiol Infect 2004; 10: 127-36.
65. Tamalet C, Henry M, Colson P, Yahi N, Poggi C, Lafeuillade A Uncommon association of T69 3-base-pair insertion plus Q151M multidrug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2004; 48: 4493-4
66. Lobato RL, Kim E-Y, Kagan RM, Merigan TC. Genotypic and phenotypic analysis of a novel 15-base insertion occurring between codons 69 and 70 of HIV type 1 reverse transcriptase. AIDS Res Human Retrovir 2002; 18: 733-6.
67. Huigen MCDG, de Graaf L, Eggink D, Schuurman R, Müller V, Boucher CAB, Nijhuis M. A novel 5 amino acid insertion in the β3-β4 loop of HIV-1 RT conferring only low-level multidrug resistance. Antivir Ther 2004; 9: S81.
68. Winters MA, Kagan RM, Kovari L, Heseltine PNR, Merigan TC. Rare one and two amino acid inserts adjacent to codon 103 of the HIV-1 reverse transcriptase (RT) affect susceptibility to nonnucleoside RT inhibitors. Antivir Ther 2005; 10: 363-6.
69. Ross L, Johnson M, Graham N, Shaefer M, St Clair M. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy. J Human Virol 1999; 2: 290-5.
70. Briones C, Mas A, Gómez-Mariano G, Altisent C, Menéndez-Arias L, Soriano V, et al. Dynamics of dominance of a dipeptide insertion in reverse transcriptase of HIV-1 from patients subjected to prolonged therapy. Virus Res 2000; 66: 13-26.
71. Lukashov VV, Huismans R, Jebbink MF, Danner SA, De Boer RJ, Goudsmit J. Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs. AIDS Res Human Retrovir 2001; 17: 807-18.
72. Bulgheroni E, Croce F, Citterio P, Viganò O, Visonà R, Sala E, et al. Unusual codon 69 insertions: influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility. J Clin Virol 2004; 29: 27-32.
73. Yahi N, Tourrès C, Tivoli N, Colson P, Dhiver C, Quinson AM, Tamalet C. Evolution of HIV-1 multidrug-resistant genotypes during combination therapy and after the cessation of antiretroviral drugs. AIDS 2000; 14: 2943-5.
74. Rousseau M-N, Vergne L, Montes B, Peeters M, Reynes J, Delaporte E, et al. Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26: 36-43.
75. Calvez V, Costagliola D, Descamps D, Yvon A, Collin G, Cécile A, et al. Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial. Antivir Ther 2002; 7: 211-8.
76. Andréoletti L, Weiss L, Si-Mohamed A, Piketty C, Prazuck T, Calamy G, et al. Multidrug-resistant HIV-1 RNA and proviral DNA variants harboring new dipeptide insertions in the reverse transcriptase pol gene. J Acquir Immune Defic Syndr 2002; 29: 102-4.
77. Larder BA, Bloor S, Kemp SD, Hertogs K, Desmet RL, Miller V, et al. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother 1999; 43: 1961-7.
78. Harrigan PR, Miller MD, McKenna P, Brumme ZL, Larder BA. Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 2002; 46: 1067-72.
79. White KL, Chen JM, Margot NA, Wrin T, Petropoulos CJ, Naeger LK, et al. Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations. Antimicrob Agents Chemother 2004; 48: 992-1003.
80. Deval J, Courcambeck J, Selmi B, Boretto J, Canard B. Structural determinants and molecular mechanisms for resistance of HIV-1 RT to nucleoside analogues. Curr Drug Metab 2004; 5: 305-16.
81. Menéndez-Arias L, Matamoros T, Deval J, Canard B. Molecular mechanisms of resistance to nucleoside analogue inhibitors of human immunodeficiency virus reverse transcriptase. Drug Design Rev - On line 2005; 2: 101-13.
82. Arion D, Kaushik N, McCormick S, Borkow G, Parniak MA. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): Increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 1998; 37: 15908-17.
83. Meyer PR, Matsuura SE, Mian AM, So AG, Scott WA. A mechanism of AZT resistance: An increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 1999; 4: 35-43.
84. Goldschmidt V, Marquet R. Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). Int J Biochem Cell Biol 2004; 36: 1687-705
85. Meyer PR, Matsuura SE, So AG, Scott WA. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci USA 1998; 95: 13471-6.
86. Tong W, Lu C-D, Sharma SK, Matsuura S, So AG, Scott WA. Nucleotide-induced stable complex formation by HIV-1 reverse transcriptase. Biochemistry 1997; 36: 5749-57.
87. Lacey SF, Reardon JE, Furfine ES, Kunkel TA, Bebenek K, Eckert KA, et al. Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3′-azido-3′-deoxythymidine. J Biol Chem 1992; 267: 15789-94.
88. Carroll SS, Geib J, Olsen DB, Stahlhut M, Shafer JA, Kuo LC. Sensitivity of HIV-1 reverse transcriptase and its mutants to inhibition by azidothymidine triphosphate. Biochemistry 1994; 33: 2113-20.
89. Kerr SG, Anderson KS. Pre-steady-state kinetic characterization of wild-type and 3′-azido-3′-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance. Biochemistry 1997; 36: 14064-70.
90. Krebs R, Immendorfer U, Thrall SH, Wohrl BM, Goody RS. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3TC. Biochemistry 1997; 36: 10292-300.
91. Chamberlain PP, Ren J, Nichols CE, Douglas L, Lennerstrand J, Larder BA, et al. Crystal structures of zidovudine and lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184 and 215. J Virol 2002; 76: 10015-9.
92. Ren J, Esnouf RM, Hopkins AL, Jones EY, Kirby I, Keeling J, et al. 3′-Azido-3′-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes. Proc Natl Acad Sci USA 1998; 95: 9518-23.
93. Caliendo AM, Savara A, An D, DeVore K, Kaplan JC, D'Aquila RT. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. J Virol 1996; 70: 2146-53.
94. Canard B, Sarfati SR, Richardson CC. Enhanced binding of azidothymidine-resistant human immunodeficiency virus 1 reverse transcriptase to the 3′-azido-3′-deoxythymidine 5′-monophosphate terminated primer. J Biol Chem 1998; 273: 14596-604.
95. Mas A, Vázquez-Alvarez BM, Domingo E, Menéndez-Arias L. Multidrug-resistant HIV-1 reverse transcriptase: Involvement of ribonucleotide-dependent phosphorolysis in cross-resistance to nucleoside analogue inhibitors. J Mol Biol 2002; 323: 181-97.
96. Lennerstrand J, Stammers DK, Larder BA. Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine. Antimicrob Agents Chemother 2001; 45: 2144-6.
97. Lennerstrand J, Hertogs K, Stammers DK, Larder BA. Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants. J Virol 2001; 75: 7202-5.
98. Meyer PR, Lennerstrand J, Matsuura SE, Larder BA, Scott WA. Effect of dipeptide insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation. J Virol 2003; 77: 3871-7.
99. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision. J Virol 2002; 76: 9143-51.
100. Matamoros T, Franco S, Vázquez-Alvarez BM, Mas A, Martínez MA, Menéndez-Arias L. Molecular determinants of multinucleoside analogue resistance in HIV-1 reverse transcriptases containing a dipeptide insertion in the fingers subdomain - Effect of mutations D67N and T215Y on removal of thymidine nucleotide analogues from blocked DNA primers. J Biol Chem 2004; 279: 24569-77.
101. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J Virol 2001; 75: 4832-42.
102. Sarafianos SG, Clark Jr AD, Das K, Tuske S, Birktoft JJ, Ilankumaran P, et al. Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. EMBO J 2002; 21: 6614-24.
103. Meyer PR, Matsuura SE, Schinazi RF, So AG, Scott WA. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2′-deoxynucleoside triphosphates. Antimicrob Agents Chemother 2000; 44: 3465-72
104. Naeger LK, Margot NA, Miller MD. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antivir Ther 2001; 6: 115-26.
105. Meyer PR, Matsuura SE, Tolun AA, Pfeifer I, So AG, Mellors JW, et al. Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2002; 46: 1540-5.
106. Nikolenko GN, Palmer S, Maldarelli F, Mellors JW, Coffin JM, Pathak VK. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: Balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci USA 2005; 102: 2093-8.
107. Prado JG, Franco S, Matamoros T, Ruiz L, Clotet B, Menéndez-Arias L, et al. Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215. Virology 2004; 326: 103-12.
108. Naeger LK, Margot NA, Miller MD. ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2002; 46: 2179-84.
109. Meyer PR, Smith AJ, Matsuura SE, Scott WA. Effects of primer-template sequence on ATP-dependent removal of chain-terminating nucleotide analogues by HIV-1 reverse transcriptase. J Biol Chem 2004; 279: 45389-98.
110. Traut TW. Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 1994; 140: 1-22.
111. Gao WY, Cara A, Gallo RC, Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1993; 90: 8925-8.
112. Back NKT, Nijhuis M, Keulen W, Boucher CAB, Oude Essink BB, van Kuilenburg ABP, et al. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996; 15: 4040-9.
113. Furman PA, Fyfe JA, St Clair MH, Weinhold K, Rideout JL, Freeman GA, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986; 83: 8333-7.
114. Terai C, Carson DA. Pyrimidine nucleotide and nucleic acid synthesis in human monocytes and macrophages. Exp Cell Res 1991; 193: 375-81.
115. Meyerhans A, Vartanian J-P, Hultgren C, Plikat U, Karlsson A, Wang L, et al. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J Virol 1994; 68: 535-40.
116. Larder BA, Chesebro B, Richman DD. Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother 1990; 34: 436-41.
117. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000; 44: 920-8.
118. Whitcomb JM, Huang W, Limoli K, Paxinos E, Wrin T, Skowron G, et al. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS 2002; 16: F41-7
119. Lin P-F, Samanta H, Rose RE, Patick AK, Trimble J, Bechtold CM, et al. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis 1994; 170: 1157-64.
120. Menéndez-Arias L, Martínez MA, Quiñones-Mateu ME, Martinez-Picado J. Fitness variations and their impact on the evolution of antiretroviral drug resistance. Curr Drug Targets - Infect Disord 2003; 3: 355-71.
121. Quiñones-Mateu ME, Tadele M, Parera M, Mas A, Weber J, Rangel HR, et al. Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation. J Virol 2002; 76: 10546-52.
122. Yerly S, Rakik A, Kinloch de Loes S, Hirschel B, Descamps D, Brun-Vézinet F, et al. Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J Virol 1998; 72: 3520-3.
123. De Ronde A, van Dooren M, van der Hoek L, Bouwhuis D, de Rooij E, van Gemen B, et al. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol 2001; 75: 595-602.
124. García-Lerma JG, Nidtha S, Blumoff K, Weinstock H, Heneine W. Increasing ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Natl Acad Sci USA 2001; 98: 13907-12.
125. Ray AS, Murakami E, Basavapathruni A, Vaccaro JA, Ulrich D, Chu CK, et al. Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis. Biochemistry 2003; 42: 8831-41.
126. Parniak MA, McBurney S, Oldfield E, Mellors JW. Bisphosphonate inhibitors of nucleoside reverse transcriptase inhibitor excision. Antivir Ther 2004; 9: S32.
127. Boyer PL, Julias JG, Marquez VE, Hughes SH. Fixed conformation nucleoside analogs effectively inhibit excision-proficient HIV-1 reverse transcriptases. J Mol Biol 2005; 345: 441-50.
128. Eckstein F. Nucleoside phosphorothioates. Annu Rev Biochem 1985; 54: 367-402.
129. Meyer P, Schneider B, Sarfati S, Deville-Bonne D, Guerreiro C, Boretto J, et al. Structural basis for activation of α-boranophosphate nucleotide analogues targeting drug-resistant reverse transcriptase. EMBO J 2000; 19: 3520-9.
130. Matamoros T, Deval J, Guerreiro C, Mulard L, Canard B, Menéndez-Arias L. Suppression of multidrug-resistant HIV-1 reverse transcriptase excision activity by α-phosphate-modified thymidine analogues. J Mol Biol 2005; 349: 451-63.
131. Sarafianos SG, Hughes SH, Arnold E. Designing anti-AIDS drugs targeting the major mechanism of HIV-1 RT resistance to nucleoside analog drugs. Int J Biochem Cell Biol 2004; 36: 1706-15.
132. McLennan AG. Dinucleoside polyphosphates - friend or foe? Pharmacol Ther 2000; 87: 73-89.
133. 4A). Acta Biochim Polon 2003; 50: 947-72.
134. 4A) as potential anti-platelet-aggregation agents. Proc Natl Acad Sci USA 1992; 89: 2370-3.
135. 4-tetraphosphate. Proc Natl Acad Sci USA 1992; 89: 11056-8.
136. 4-tetraphosphate: A novel antiplatelet agent. Proc Natl Acad Sci USA 1997; 94: 4034-9.
137. Meyer P, Smith A, Matsuura S, Scott W. Dinucleoside polyphosphates are novel inhibitors of HIV-1 reverse transcriptase with increased potency against enzymes containing AZT-resistance mutations. Antivir Ther 2004; 9: S37.
138. Ross L, Johnson M, Ferris RG, Short SA, Boone LR, Melby TE, et al. Deletions in the β3-β4 hairpin loop of HIV-1 reverse transcriptase are observed in HIV-1 isolated from subjects during long-term antiretroviral therapy. J Human Virol 2000; 3: 144-9.
139. Giri J, Rueda HJ, Monticelli A, Planes N. Case report of a novel amino acid deletion of in codon 67 and T69G substitution in the reverse transcriptase of HIV-1. Antivir Ther 2000; 5: 227-8.
140. Giri J, Jaureguli RH, Monticelli A, Pirola DA, Planes N. Infrequent deletion in 67 codon in HIV reverse transcriptase in antiretroviral treatment failure. Medicina (Buenos Aires) 2001; 61: 193-5.
141. Masciari R, Cosco L, Diaco MC, Della DN, Ferraro T, Raimondi T, Ruperti B, Santandrea E. HIV-1: a case of RT67 deletion in a multi-treated non responder patient. New Microbiol 2002; 25: 83-8.
142. Winters MA, Coolley KL, Cheng P, Girard YA, Hamdan H, Kovari LC, et al. Genotypic, phenotypic, and modeling studies of a deletion in the β3-β4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors. J Virol 2000; 74: 10707-13.
143. Beerenwinkel N, Schmidt B, Walter H, Kaiser R, Lengauer T, Hoffmann D, et al. Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. Proc Natl Acad Sci USA 2002; 99: 8271-6.
144. Gonzales MJ, Wu TD, Taylor J, Belitskaya I, Kantor R, Israelski D, et al. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 2003; 17: 791-9.
145. Weber J, Chakraborty B, Weberova J, Miller MD, Quiñones-Mateu ME. Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation. J Clin Microbiol 2005; 43: 1395-400.
146. Imamichi T, Sinha T, Imamichi H, Zhang Y-M, Metcalf JA, Falloon J, et al. High-level resistance to 3′-azido-3′-deoxythymidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1. J Virol 2000; 74: 1023-8.
147. Imamichi T, Berg SC, Imamichi H, Lopez JC, Metcalf JA, Falloon J, Lane HC. Relative replication fitness of a high-level 3′-azido-3′-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr→Gly) at codon 69. J Virol 2000; 74: 10958-64.
148. Winters MA, Merigan TC. Variants other than aspartic acid at codon 69 of the human immunodeficiency virus type 1 reverse transcriptase gene affect susceptibility to nucleoside analogs. Antimicrob Agents Chemother 2001; 45: 2276-9.
149. Imamichi T, Murphy MA, Imamichi H, Lane HC. Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles. J Virol 2001; 75: 3988-92.
150. Boyer PL, Imamichi T, Sarafianos SG, Arnold E, Hughes SH. Effects of the Δ67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision. J Virol 2004; 78: 9987-97.
151. Suzuki K, Kaufmann GR, Mukaide M, Cunningham P, Harris C, Leas L, et al. Novel detection of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine. AIDS Res Human Retrovir 2001; 17: 1293-6.
152. Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran CT. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 2005; 11(14): 1805-43.
153. Imamichi T. Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors. Curr Pharm Des 2004; 10(32): 4039-53.
154. Pereira CF, Paridaen JT. Anti-HIV drug development - an overview. Curr Pharm Des 2004; 10(32): 4005-37.